Mga Batayang Estadistika
| CIK | 1593184 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioRegenx, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
Sublicense and Assignment Agreement dated May 5, 2025 Exhibit 10.1 SUBLICENSE AND ASSIGNMENT AGREEMENT Dated 5 May 2025 This Agreement is made between 1. Universiteit Maastricht, a public-law entity incorporated under the laws of the Netherlands and registered with the Commercial Register under number 50169181, with statutory seat in Maastricht, the Netherlands and place of business at Minderbroedersberg 4, 6211 LK Maastricht, the Netherlands (“UM”); |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56345 BIOREGENX, INC. (Exact nam |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56345 BIOREGENX, INC. (Exact na |
|
| April 16, 2025 |
Exhibit 21 Subsidiaries Microvascular Health Solutions, LLC. (DE) MyBodyRx, LLC (DE) Findit Ai Connect, Inc. (Findit Ai) (NV) NuLife Sciences, Inc. (NV) DocSun Biomedical Holdings, Inc. (DocSun) (FL) |
|
| April 16, 2025 |
Exhibit 14 CODE OF ETHICS AND BUSINESS CONDUCT FOR OFFICERS, DIRECTORS AND EMPLOYEES OF BIOREGENX, INC. |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:000-5 |
|
| April 16, 2025 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Our common stock, par value $0.001 per share, is registered under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and is quoted under the symbol BRGX on the OTC Pink Current Market. The quotations represent inter-dealer prices with |
|
| April 16, 2025 |
Exhibit 19 Adopted by the Board of Directors on March 3, 2022. BioRegenx, Inc. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES* March 3, 2022 A Statement of Company Policy on Insider Trading and Policy Regarding Special Trading Procedures (collectively, this “Policy”) is being provided to you. You should read this Policy, address questions to Sherri A |
|
| April 15, 2025 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Our common stock, par value $0.001 per share, is registered under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and is quoted under the symbol BRGX on the OTC Pink Current Market. The quotations represent inter-dealer prices with |
|
| April 15, 2025 |
Exhibit 14 CODE OF ETHICS AND BUSINESS CONDUCT FOR OFFICERS, DIRECTORS AND EMPLOYEES OF BIOREGENX, INC. |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:000-56345 BIOREGENX, IN |
|
| April 15, 2025 |
Exhibit 21 Subsidiaries Microvascular Health Solutions, LLC. (DE) MyBodyRx, LLC (DE) Findit Ai Connect, Inc. (Findit Ai) (NV) NuLife Sciences, Inc. (NV) DocSun Biomedical Holdings, Inc. (DocSun) (FL) |
|
| April 15, 2025 |
Exhibit 19 Adopted by the Board of Directors on March 3, 2022. BioRegenx, Inc. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES* March 3, 2022 A Statement of Company Policy on Insider Trading and Policy Regarding Special Trading Procedures (collectively, this “Policy”) is being provided to you. You should read this Policy, address questions to Sherri A |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2025 BIOREGENX, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-56345 (Commission File Number) 30-191245 |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-49819 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o N-CSR For Period Ended: December 31, 2024 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 15, 2025 BIOREGENX, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-56345 (Commission File Number) 30-191 |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56345 BIOREGENX, INC. (Exac |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 7, 2024 BIOREGENX, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-56345 (Commission File Number) 30-1912 |
|
| October 9, 2024 |
Exhibit 2.2 AGREEMENT AND PLAN OF MERGER AGREEMENT AND PLAN OF MERGER (this “Merger Agreement”) made and entered into effective December 29, 2022 by and between BioRegenx, Inc., a Nevada corporation (“BioRegenx”) and Findit, Inc., a Nevada corporation (“Findit”). WITNESSETH: WHEREAS, BioRegenx is a corporation duly organized and existing under the laws of the state of Nevada; WHEREAS, Findit is a |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56345 BIOREGENX, INC. (Exact nam |
|
| October 9, 2024 |
Exhibit 2.1 SECURITIES EXCHANGE AGREEMENT THIS SECURITIES EXCHANGE AGREEMENT (the “Agreement”) is made effective on 12/5/2023 . AMONG: BioRegenx, Inc. a corporation existing under the laws of the State of Nevada, having a registered office at 7407 Ziegler Road, Chattanooga, Tennessee 37421 (hereinafter referred to as the “BioRegenx”) - and - DocSun Biomedical Holdings, Inc. a corporation existing |
|
| October 9, 2024 |
Exhibit 4.2 THE SECURITIES REPRESENTED HEREBY, INCLUDING THE SHARES ISSUABLE UPON EXERCISE HEREOF, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAW |
|
| October 9, 2024 |
Form of 2024 16% Convertible Note Exhibit 4.1 THIS INSTRUMENT AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR UPON RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL SATISFACTORY TO THE C |
|
| October 9, 2024 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.3 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Bioregenx Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Bioregenx, Inc. (the “Company”) as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders’ equity (deficiency), and cash flows for |
|
| October 9, 2024 |
Form of 2024 16% Convertible Note Purchase Agreement Exhibit 10.1 THESE ARE SPECULATIVE SECURITIES WHICH INVOLVE A HIGH DEGREE OF RISK. IN MAKING AN INVESTMENT DECISION, PURCHASERS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY AND THE TERMS OF THE OFFERING, INCLUDING THE RISKS INVOLVED. THE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2024 BIOREGENX, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-56345 (Commission File Number) 30-1912 |
|
| October 9, 2024 |
Exhibit 10.1 + DISTRIBUTORSHIP AGREEMENT This DISTRIBUTORSHIP AGREEMENT (the “Agreement”) is entered in as of the 1st day of December, 2014 (the “Effective Date”) Between: MicroVascular Health Solutions, LLC, a company located at PO Box 332, American Fork, Utah 84003 U.S.A. (“DISTRIBUTOR”) and: Glycocheck B.V, a Dutch company organized under the laws of the Netherlands having a place of business a |
|
| October 9, 2024 |
FINDIT, INC Pro Forma Condensed Consolidated Balance Sheet As of December 31, 2023 Exhibit 99.4 FINDIT, INC Pro Forma Condensed Consolidated Balance Sheet As of December 31, 2023 (Unaudited) Findit, Inc BioRegenx Inc. and Subsidiaries Transaction Accounting Adjustments Notes Proforma (Unaudited) ASSETS Current Assets: Cash and cash equivalents $ – $ 125,402 $ – $ 125,402 Accounts receivable – 32,581 – 32,581 Inventories – 217,529 – 217,529 Prepaid expenses and other current asse |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 2 ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56345 BIOREGE |
|
| October 9, 2024 |
Exhibit 10.2 AGREEMENT THIS AGREEMENT is entered into this 13th day of May 2015 (the ''Effective Date"), by and between the "VHS Parties" and the "MVHS Parties," as these terms are defined herein. RECITALS WHEREAS, as used herein, the term "VHS Parties" shall collectively refer to VASCULAR HEALTH SCIENCES, LLC, a Delaware limited liability company ("VHS"), THEODORE C. SKOKOS, an individual, LOAN P |
|
| August 12, 2024 |
NT 10-Q 1 bioregenxext.htm EXTENSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-49819 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o N-CSR For Period Ended: June 30, 2024 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2024 BIOREGENX, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-56345 (Commission File Number) 30-191245 |
|
| July 22, 2024 |
Libertas Trust 7639 Davidson Road Chattanooga, TN 37421 July 22, 2024 Libertas Trust 7639 Davidson Road Chattanooga, TN 37421 July 22, 2024 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: BioRegenx, Inc. |
|
| July 22, 2024 |
BRGX / BioRegenx, Inc. / Libertas Trust - AMENDMENT TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 BioRegenx, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 31772N209 (CUSIP Number) J.M. Walker & Associates 7841 South Garfield Way Centennial, CO 80122 (303) 850-7637 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Comm |
|
| July 19, 2024 |
BRGX / BioRegenx, Inc. / JARA Trust - AMENDMENT TO SCHEDULE 13D Activist Investment SC 13D/A 1 bioregenxsc13da-jara.htm AMENDMENT TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 BioRegenx, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 31772N209 (CUSIP Number) J.M. Walker & Associates 7841 South Garfield Way Centennial, CO 80122 (303) 850-7637 (Name, Address and Tel |
|
| July 19, 2024 |
WILSHIRE HOLDING TRUST 9718 Catttails View Cove Ooltewah, TN 37363 July 19, 2024 WILSHIRE HOLDING TRUST 9718 Catttails View Cove Ooltewah, TN 37363 July 19, 2024 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: BioRegenx, Inc. |
|
| July 19, 2024 |
BRGX / BioRegenx, Inc. / Wilshire Holdings Trust - AMENDMENT TO SCHEDULE 13D Activist Investment SC 13D/A 1 bioregenxsc13da-wilshire.htm AMENDMENT TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 BioRegenx, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 31772N209 (CUSIP Number) J.M. Walker & Associates 7841 South Garfield Way Centennial, CO 80122 (303) 850-7637 (Name, Address and |
|
| July 19, 2024 |
JARA TRUST 1001 Michael Lane Eagleville, PA 19403 July 19, 2024 JARA TRUST 1001 Michael Lane Eagleville, PA 19403 July 19, 2024 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: BioRegenx, Inc. |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2024 BIOREGENX, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-56345 (Commission File Number) 30-191245 |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2024 BIOREGENX, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-56345 (Commission File Number) 30-1912453 |
|
| May 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment 1 ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000 |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56345 BIOREGE |
|
| May 16, 2024 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2024 BIOREGENX, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-56345 (Commission File Number) 30-1912453 |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-49819 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o N-CSR For Period Ended: March 31, 2024 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q For |
|
| April 29, 2024 |
FDIT / Findit, Inc. / Libertas Trust - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 BioRegenx, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 31772N209 (CUSIP Number) J.M. Walker & Associates 7841 South Garfield Way Centennial, CO 80122 (303) 850-7637 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Commun |
|
| April 29, 2024 |
FDIT / Findit, Inc. / JARA Trust - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 BioRegenx, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 31772N209 (CUSIP Number) J.M. Walker & Associates 7841 South Garfield Way Centennial, CO 80122 (303) 850-7637 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Commun |
|
| April 29, 2024 |
FDIT / Findit, Inc. / Libertas Trust - SCHEDULE 13D Activist Investment SC 13D/A 1 bioregenxlibertas.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 BioRegenx, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 31772N209 (CUSIP Number) J.M. Walker & Associates 7841 South Garfield Way Centennial, CO 80122 (303) 850-7637 (Name, Address and Telephone Number of P |
|
| April 29, 2024 |
FDIT / Findit, Inc. / Wilshire Holdings Trust - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 BioRegenx, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 31772N209 (CUSIP Number) J.M. Walker & Associates 7841 South Garfield Way Centennial, CO 80122 (303) 850-7637 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Commun |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-1593184 BIOREGENX, |
|
| April 1, 2024 |
Certificate of Designation of Series A Preferred Shares filed March 14, 2024 Exhibit 3.7 Business Number C30222 - 1998 Filed in the Office of Secretary of State State Of Nevada Filing Number 20243915583 Filed On 3/14/2024 11:02:00 AM Number of Pages 2 1 11 : 02 : 21 a . m . 03 - 14 - 2024 4 I 307 - 263 - 0459 Fr o m Ro bert Doran 1.307.263.0 4 59 Thu Mar 14 12:02:32 2024 MDT Page 4 of 4 ATTACHMENT TO CERTlFICATE OF DESIGNATION SERIES A PREFERRED STOCK Pursuant to the Nevad |
|
| April 1, 2024 |
Certificate of Amendment to Articles of Incorporation filed on March 8, 2024 Exhibit 3.6 Business Number C30222 - 1998 Filed in the Office of Secretary of State State Of Nevada Filing Number 20243904816 Filed On 3/8/2024 2:14:00 PM Number of Pages 3 1 DocuSign Envelope ID : 1052F269 - 1F 78 - 490C - 9 175 - 0 322 44BA4744 FRANCISCO V. AGUILAR Secretary of State 401 North Carson Street Carson City , Nevada 89701 - 4201 (775) 684 - 5708 Website : www.nvsos.gov 4 T 5 C c 6 ( |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-49819 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o N-CSR For Period Ended: December 31, 2023 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q |
|
| April 1, 2024 |
CHATTANOOGA, TN / ACCESSWIRE / March 14, 2024 / Exhibit 99.2 CHATTANOOGA, TN / ACCESSWIRE / March 14, 2024 / On March 8, 2024, the merger of BioRegenx, Inc. into Findit, Inc. (OTC PINK:FDIT) went effective along with the name change of the surviving entity to BioRegenx, Inc., by the state of Nevada and the SEC. Furthermore, BioRegenx is currently collaborating with FINRA to facilitate a name and symbol change. The company is diligently working |
|
| April 1, 2024 |
Articles of Merger dated March 8, 2024 Exhibit 3.5 Business Number C30222 - 1998 Filed in the Office of Secretary of State State Of Nevada Filing Number 20243855737 Filed On 2/26/2024 3:00:00 PM Number of Pages 4 1 Exchange /Me rger: Owner's approval (NRS 92A . 200) (options a, b or c must be used for each entity ) D A. Owner's approval was not required from the: D Acquired/merging D Acquiring/surviving D B. The plan was approved by th |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2024 BIOREGENX, INC. (formerly FINDIT, INC.) (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-56345 (Commissio |
|
| April 1, 2024 |
Certificate of Correction dated March 26, 2024 Exhibit 3.8 ) L O HI GL F %HL XQ VR LIWQ KH HV V 2 I 1 X & ) L O L Q J 1 X P E H 6 H F U H W ) D L O U \ H G R I 2 Q 6 W D W X P H U R I 6 W D W H 1 2 I E 1 H Y D G D 3 D |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement FINDIT, INC. (Name of Registrant As |
|
| January 16, 2024 |
FINDIT, INC. 5051 Peachtree Corners Circle, #200 Peachtree Corners, GA 30092 January 16, 2024 FINDIT, INC. 5051 Peachtree Corners Circle, #200 Peachtree Corners, GA 30092 January 16, 2024 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Findit, Inc. Revised Information Statement on Schedule 14C Filed January 3, 2024 File No. 000-56345 Dear Sir or Madam: Pursuant to your comment letter dated January 11, 2024, please note the following: Revised Information Stateme |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement FINDIT, INC. (Name of Registrant As |
|
| January 3, 2024 |
FINDIT, INC. 5051 Peachtree Corners Circle, #200 Peachtree Corners, GA 30092 January 3, 2024 FINDIT, INC. 5051 Peachtree Corners Circle, #200 Peachtree Corners, GA 30092 January 3, 2024 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Findit, Inc. Preliminary Information Statement on Schedule 14C – amendment 1 Filed February 23, 2023 File No. 000-56345 Dear Sir or Madam: Pursuant to your call on February 28, 2023, please note the following: Preliminary Informat |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement FINDIT, INC. (Name of Registrant As |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56345 FINDIT, INC. (Exact n |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-56345 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o N-CSR For Period Ended: September 30, 2023 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56345 FINDIT, INC. (Exact name o |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-49819 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o N-CSR For Period Ended: June 30, 2023 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q For |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56345 FINDIT, INC. (Exact name |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-56345 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o N-CSR For Period Ended: March 31, 2023 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q For |
|
| April 4, 2023 |
EXHIBIT 3.3 Business Number C30222 - 1998 Filed in the Office of Secretary of State State Of Nevada Filing Number 20150569632 - 19 Filed On 12/30/2015 Number of Pages 1 |
|
| April 4, 2023 |
EXHIBIT 3.4 Business Number C30222 - 1998 Filed in the Office of Secretary of State State Of Nevada Filing Number 20160138821 - 92 Filed On 03/29/2016 Number of Pages 1 |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56345 FINDIT, INC. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 000-49819 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o N-CSR For Period Ended: December 31, 2022 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q |
|
| February 23, 2023 |
FINDIT, INC. 5051 Peachtree Corners Circle, #200 Peachtree Corners, GA 30092 February 22, 2023 FINDIT, INC. 5051 Peachtree Corners Circle, #200 Peachtree Corners, GA 30092 February 22, 2023 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Findit, Inc. Preliminary Information Statement on Schedule 14C Filed February 7, 2023 File No. 000-56345 Dear Sir or Madam: Pursuant to your comment letter dated February 17, 2023, please note the following: Preliminary Informat |
|
| February 23, 2023 |
PRER14C 1 prer14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement FINDIT, INC. ( |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement FINDIT, INC. (Name of Registrant As |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement FINDIT, INC. (Name of Registrant As |
|
| January 6, 2023 |
Findit, Inc. and BioRegenx, Inc. Announce they have Entered into a Definitive Agreement to Merge EX-99.1 2 ex991pr.htm PRESS RELEASE Exhibit 99.1 Findit, Inc. and BioRegenx, Inc. Announce they have Entered into a Definitive Agreement to Merge ATLANTA, GA / ACCESSWIRE / December 29, 2022 / Findit, Inc., a Nevada Corporation (OTC PINK:FDIT), owner of Findit.com, a full-service social networking platform that provides tools for members to increase brand awareness through content creation and sha |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 29, 2022 FINDIT, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 333-254128 (Commission File Number) 30-1912 |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-254128 FIN |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K ? Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2022 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-254128 FINDIT, |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-254128 FINDIT, |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K ? Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2022 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on F |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to FINDIT, INC (Exact name of registrant as specif |
|
| March 30, 2022 |
NT 10-K 1 fditnt10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): þ Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2021 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10 |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 333-254128 FIN |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K ? Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2021 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report |
|
| September 24, 2021 |
PROSPECTUS Findit, Inc. 10,000,000 shares of common stock being offered by Findit, Inc. at a fixed price of $0.30. The shares of stock to be sold include: a) 10,000,000 shares, are being offered for sale to investors on a best-efforts basis a price of $0.30 per share. Upon the effectiveness of this prospectus: the Selling Shareholder may sell the shares as detailed in the section entitled "Plan of |
|
| September 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 FindIt, Inc. |
|
| September 20, 2021 |
FindIt, Inc. 5051 Peachtree Corners Circle, #200 Peachtree Corners, GA 30092 Telephone: (404) 443-3224 September 20, 2021 VIA EDGAR TRANSMISSION U. S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street N.E. Washington, DC 20549 Attn: Mr. Edwin Kim, Attorney Advisor Re: FindIt, Inc. File No.: 333-254128 Request for Acceleration of Effectiveness Ladies and Gentlemen: Purs |
|
| September 2, 2021 |
AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 1, 2021 REGISTRATION NO. 333-254128 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 6 TO FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Findit, Inc. (Exact name of registrant as specified in its charter) Nevada 7370 30-1912453 (State or Other Jurisdiction (Primary Stand |
|
| September 1, 2021 |
THE LAW OFFICES OF THOMAS C. COOK ATTORNEY AND COUNSELOR AT LAW 10470 W. CHEYENNE AVENUE, SUITE 530, PMB 303 LAS VEGAS, NEVADA 89129 (702) 524-9151 [email protected] September 1, 2021 Edwin Kim, Attorney Advisor U.S. Securities and Exchange Commission Division of Corp. Finance, Office of Technology Washington, DC 20549 Re: Findit, Inc. Amendment No. 5 to Registration Statement on Form S-1 Filed Augus |
|
| August 31, 2021 |
AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON AUGUST 31, 2021 REGISTRATION NO. 333-254128 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Findit, Inc. (Exact name of registrant as specified in its charter) Nevada 7370 30-1912453 (State or Other Jurisdiction (Primary Standar |
|
| July 16, 2021 |
CORRESP 1 filename1.htm THE LAW OFFICES OF THOMAS C. COOK ATTORNEY AND COUNSELOR AT LAW 10470 W. CHEYENNE AVENUE, SUITE 530, PMB 303 LAS VEGAS, NEVADA 89129 (702) 524-9151 [email protected] July 16, 2021 Edwin Kim, Attorney Advisor U.S. Securities and Exchange Commission Division of Corp. Finance, Office of Technology Washington, DC 20549 Re: Findit, Inc. Amendment No. 1 to Registration Statement on |
|
| July 16, 2021 |
AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON JULY 16, 2021 REGISTRATION NO. 333-254128 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Findit, Inc. (Exact name of registrant as specified in its charter) Nevada 7370 30-1912453 (State or Other Jurisdiction (Primary Standard |
|
| June 24, 2021 |
AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON JUNE 23, 2021 REGISTRATION NO. 333-254128 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Findit, Inc. (Exact name of registrant as specified in its charter) Nevada 7370 30-1912453 (State or Other Jurisdiction (Primary Standard |
|
| June 23, 2021 |
THE LAW OFFICES OF THOMAS C. COOK ATTORNEY AND COUNSELOR AT LAW 10470 W. CHEYENNE AVENUE, SUITE 530, PMB 303 LAS VEGAS, NEVADA 89129 (702) 524-9151 [email protected] June 23, 2021 Edwin Kim, Attorney Advisor U.S. Securities and Exchange Commission Division of Corp. Finance, Office of Technology Washington, DC 20549 Re: Findit, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed April 28, |
|
| May 25, 2021 |
AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON MAY 24, 2021 REGISTRATION NO. 333-254128 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Findit, Inc. (Exact name of registrant as specified in its charter) Nevada 7370 30-1912453 (State or Other Jurisdiction (Primary Standard I |
|
| May 24, 2021 |
THE LAW OFFICES OF THOMAS C. COOK ATTORNEY AND COUNSELOR AT LAW 10470 W. CHEYENNE AVENUE, SUITE 530, PMB 303 LAS VEGAS, NEVADA 89129 (702) 524-9151 [email protected] May 24, 2021 Edwin Kim, Attorney Advisor U.S. Securities and Exchange Commission Division of Corp. Finance, Office of Technology Washington, DC 20549 Re: Findit, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed April 28, |
|
| April 28, 2021 |
AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON MARCH 10, 2021 REGISTRATION NO. 333-254128 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Findit, Inc. (Exact name of registrant as specified in its charter) Nevada 7370 30-1912453 (State or Other Jurisdiction (Primary Standard |
|
| April 27, 2021 |
THE LAW OFFICES OF THOMAS C. COOK ATTORNEY AND COUNSELOR AT LAW 10470 W. CHEYENNE AVENUE, SUITE 530, PMB 303 LAS VEGAS, NEVADA 89129 (702) 524-9151 [email protected] April 27, 2021 Edwin Kim, Attorney Advisor U.S. Securities and Exchange Commission Division of Corp. Finance, Office of Technology Washington, DC 20549 Re: Findit, Inc. Registration Statement on Form S-1 Filed March 11, 2021 File No. 333 |
|
| March 11, 2021 |
Amended Designation filed with the State of Nevada on 12/30/15 Exhibit 3.2 BYLAWS OF Findit, Inc. (the "Corporation") STOCKHOLDERS (the "Stockholders") Annual Meeting 1. A meeting of the Stockholders will be held annually for the purpose of electing directors (the "Directors") of the Corporation and for the purpose of doing other business as may come before the meeting. If the day fixed for the annual meeting is a legal holiday in the State of Nevada, the ann |
|
| March 11, 2021 |
Articles of Incorporation dated December 23, 1998 Exhibit 3.1 ? Articles of Incorporation Filed in the office of /s/ Dean Heller Dean Heller Secretary of State State of Nevada Filing Date 12/23/1998 Entity Number C30222-1998 ARTICLES OF INCORPORATION OF KNOWLEDGE NETWORKS, INC. The undersigned has, this day, formed corporation pursuant to Chapter 78 of the Nevada Revised Statutes for the transaction of business, and the promotion and conduct of t |
|
| March 11, 2021 |
S-1 1 finditbdy.htm AS FILED WITH THE U. S. SECURITIES AND EXCHANGE COMMISSION ON MARCH 11, 2021 REGISTRATION NO. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Findit, Inc. (Exact name of registrant as specified in its charter) Nevada 7370 30-1912453 (State or Other Jurisdiction (Primary Standard Indust |
|
| March 11, 2021 |
EX-99.1 6 ex991subagr.htm SUBSCRIPTION AGREEMENT Exhibit 99.1 SUBSCRIPTION AGREEMENT Findit, Inc. 5051 Peachtree Corners Circle, #200 Peachtree Corners, Georgia 30092 Re: Prospectus, dated 2021 Dear Mr. Firth: The undersigned investor ("Investor") in this Subscription Agreement ("Agreement") hereby acknowledges receipt of the prospectus ("Prospectus"), dated , 2021 of Findit, Inc., a Nevada corpor |
